Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Matthew Harris"


5 mentions found


Royal Academy of Arts, London / David ParryLondon has long been home to some of the world's leading art galleries — Tate Modern, Somerset House and the National Gallery are among the U.K.'s most visited attractions. CNBC asked a mix of artists to name their favorite public and commercial galleries to visit in London — large or small. Contemporary galleries — and an upscale hotelMultidisciplinary artist Lauren Baker, who is exhibiting at the Venice Biennale until November, named contemporary galleries — and a hotel — as her favorite places to see art in London. Her top London galleries include the Royal Academy of Arts, for its "wonderful" exhibitions, she told CNBC by email. Rob Stothard | Getty ImagesEdwards also likes major London galleries Tate Modern and Tate Britain.
Persons: David Parry London, Lauren Baker, Alice, It's, Rachael Louise Bailey, Matthew Harris, Baker, Woolff, Apolline Bokkerink, Joanne Tinker, Jeff Greenberg, Matthew Flower, Amanda Wilkinson —, Maureen Paley, Gillian Wearing, Wolfgang Tillmans, Ratnam, Katharine Edwards, Mark Rothko's, Rothko, Rob Stothard, Edwards, Mark Rothko, Komal Madar, Kandinsky, Munter, Komal, Madar, Judy Chicago's, Modigliani, Gilbert Proesch, George Passmore, Gilbert, Joe Maher, Tom Oldham, Dave Grohl, Usain Bolt, Gilbert Prousch, Oldham, Queen Elizabeth II, Andy Warhol, Phillips, Dan Kitwood Organizations: Royal Academy of Arts, Royal Academy of Arts ,, Somerset House, CNBC, Venice Biennale, Alice Black Gallery, Universal, Getty, Turner, Tate Galleries, Cricket Fine, London's Tate, Tate, Tate Britain, Seagram, Gilbert & George Centre, Oldham, George Centre, . Locations: London, Royal Academy of Arts , London, Venice, London's Soho, Fitzrovia, Mayfair, Andalusia, Spain, London's Chelsea, New York, Serpentine, Hyde, London's Bermondsey, Islington, Soho, England
Morgan Stanley thinks that one of Sarepta Therapeutics ' drugs will receive accelerated approval from the Food and Drug Administration — creating a promising investing opportunity. Analyst Matthew Harrison upgraded Sarepta shares to overweight from equal weight, saying that the path for SRP-9001, an investigational gene therapy for Duchenne muscular dystrophy (DMD), now appears "de-risked." Morgan Stanley said that with the accelerated launch of SRP-9001, Sarepta has potential for over $5 billion in peak sales. To be sure, Harrison said potential risks to a downside include updates to the DMD gene therapy program, as well as manufacturing and regulatory risks. Data from competitors could also negatively impact Sarepta's position in the DMD market, the analyst noted.
Revenue for the quarter came in at $663 million, falling well below analysts' estimates of $742 million, according to Refinitiv. Sarepta Therapeutics — The biotech stock soared by 17% after Morgan Stanley upgraded Sarepta shares to overweight from equal weight. Kohl's reported a loss of $2.49 per share on $5.78 billion of revenue. Analysts surveyed by Refinitiv had expected positive earnings of 98 cents per share on $5.99 billion of revenue. Monster reported $1.51 billion in revenue, falling short of analysts' expectations of $1.6 billion.
Morgan Stanley views biotechnology as an area of the market that abounds with opportunity heading into 2023. It's been a painful year for the investors — and once high-flying growth stocks — as the Federal Reserve's rate hikes lead to fears of a slowing economy. Morgan Stanley also expects mergers and acquisitions activity to pick up in 2023 given the piles of cash some companies have on hand. Here are some of the stocks Morgan Stanley recommends heading into the new year: Harrison named BeiGene among the bank's biotech stock picks heading into the new year. "We expect 2023 to finally be the year that commercial upside can drive BMRN higher," Harrison wrote.
Analyst Matthew Harrison's price target of $851 implies 20% upside from Thursday's close. Regeneron is already trading above its average analyst price target, according to FactSet. Still, SolarEdge has 17.5% upside, according to the average price target. Lastly, Norwegian Cruise Line Holdings rallied 11% so far this week and it has another 17.5% upside to the average analyst price target, according to FactSet. On Monday, Stifel analyst Steven Wieczynski reiterated his $26 price target , which suggests 82% upside from Thursday's close.
Total: 5